Abstract

Epigenetic modifications control cancer development and clonal evolution in various cancer types. Here, we show that loss of the male-specific histone demethylase lysine-specific demethylase 5D (KDM5D) encoded on the Y chromosome epigenetically modifies histone methylation marks and alters gene expression, resulting in aggressive prostate cancer. Fluorescent in situ hybridization demonstrated that segmental or total deletion of the Y chromosome in prostate cancer cells is one of the causes of decreased KDM5D mRNA expression. The result of ChIP-sequencing analysis revealed that KDM5D preferably binds to promoter regions with coenrichment of the motifs of crucial transcription factors that regulate the cell cycle. Loss of KDM5D expression with dysregulated H3K4me3 transcriptional marks was associated with acceleration of the cell cycle and mitotic entry, leading to increased DNA-replication stress. Analysis of multiple clinical data sets reproducibly showed that loss of expression of KDM5D confers a poorer prognosis. Notably, we also found stress-induced DNA damage on the serine/threonine protein kinase ATR with loss of KDM5D. In KDM5D-deficient cells, blocking ATR activity with an ATR inhibitor enhanced DNA damage, which led to subsequent apoptosis. These data start to elucidate the biological characteristics resulting from loss of KDM5D and also provide clues for a potential novel therapeutic approach for this subset of aggressive prostate cancer.

Guidelines:
The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We
will not post data that have not been subjected to peer review, nor will we post letters that are
essentially a reiteration of another letter. We reserve the right to edit any letter for length, content, and clarity.
Authors will be notified by e-mail if their letters were accepted. No appeals will be considered.

Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain
text or HTML. The author's name and e-mail address are required, and will be posted with the letter. All
possible conflicts of interest must be noted, even if they are not posted. If you wish to include a
figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editors
directly at editors@the-jci.org.

First nameThis field is required

Last nameThis field is required

PositionThis field is required

InstitutionThis field is required

Email addressThis field is required

Other authors (Enter the list of colleagues in the following form: Stephanie Fulton, Thomas L. Wilding, and Frances Groen.)